Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis (CILIA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Luca Vittorio Carlo Valenti, Doctor
- Phone Number: 56595 02 5503 6595
- Email: luca.valenti@policlinico.mi.it
Study Locations
-
-
MI
-
Milan, MI, Italy, 20122
- Recruiting
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
-
Contact:
- Luca Valenti, Doctor
- Phone Number: 02 5503 6595
- Email: luca.valenti@policlinico.mi.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Between 18 and 90 years of age
- Of both sexes
- willingness to sign informed consent for the study; Additional criteria group 1
- Patients with a confirmed aPSC diagnosis Additional criteria group 2
- patients with suspected PSC liver biopsy candidates Additional criteria group 3
- Patients not affected by aPSC listed for the following procedures:
- Liver resection for hepatocellular or other hepatic lesions (including secondary effects from other cancers and benign focal lesions, which will result in healthy liver tissue);
- Post-transplant biopsies of healthy liver;
- cholecystectomies. Additional criteria group 4
- Patients previously genotyped in the study "Impact of complete exoma sequencing on clinical management of patient with non-alcoholic liver steatosis and cryptogenic liver disease project code RF-2016-02364358" results carrying gene variants associated with ciliopathies
Exclusion Criteria:
-Positive for chronic viral hepatitis (HCV-RNA and HBsAg).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Behaviour of the genetic variants involved in ciliopathies.
Study of the onset and progression of aPSC by analyzing in three-dimensional models called assembloids:
|
Using extracellular vesicles containing the CRISPR/Cas9 genome editing system that by faithfully reproducing the in vivo part will allow a more faithful response than the use of conventional 2D model, organoids or animal model.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The quantify the impact of genetic risk factors for PSC and the role genetic variants
Time Frame: 48 months
|
The different inclusion criteria are able to identify the number of individuals at risk for PSC among patients.
Understand the impact of individual genetic variants on PSC risk and rates variants associated with ciliopathies on aPSC phenotype within the variant carrier group compared to the non-carrier group.
|
48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The quantify the impact of pharmacological tests on extracellular vesicles
Time Frame: 48 months
|
The impact of genetic risk factors for PSC and their interaction will be realized by evaluating the extracellular vesicles of the CRISPR/Cas9 genome editing system to correct mutations involved in ciliopathies.
|
48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CILIA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.